ARCHIVES

Celebrex Studied As Potential Prevention Of Lung Cancer In High-Risk Populations

This article is from The Cancer Letter archive.

Vol. 24 No. 8 | August 31, 2001

Download PDF Visit The Full Archive

Related Articles

ODAC Meets at ASCO, Recommends Approval Of Dasatinib For CML.

June 9, 2006

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

DRCCA Board Again Approves Breast Cancer Dietary Study

May 13, 1983

ACCC Presentations On Care In Community

March 27, 1981

AACR 2014 Cancer Progress Report: More Federal Funds Needed

September 19, 2014

NCI Programs: Advisors Approve Plans For New Grants In Imaging Research

July 10, 1998